Clovis Oncology CLVS announced today that an abstract
discussing the findings of the ongoing Phase I portion of the Phase I/II
clinical study of CO-1686 has been accepted for Proffered Paper (Oral)
presentation during the 4th European Lung Cancer Conference
(ELCC). CO-1686 is the Company's novel, oral, targeted covalent
(irreversible) inhibitor of mutant forms of the epidermal growth factor
receptor (EGFR) for the treatment of non-small cell lung cancer (NSCLC)
in patients with initial activating EGFR mutations as well as the
dominant resistance mutation T790M. The conference takes place March
26-29, 2014 in Geneva, Switzerland.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in